Peptide based Nanoparticles as Ocular Drug Delivery Vehicles
This project will develop methodology for the manufacture of novel peptide-based nanoparticles and nanocapsules to satisfy an unmet clinical need: sustained drug delivery to the posterior segment of the eye. The proposed consortiu...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
CTQ2010-20541-C03-02
SINTESIS DE NANOPARTICULAS POLIMERICAS PARA DRUG-DELIVERY Y...
66K€
Cerrado
NanoPol
Soft Biocompatible Polymeric Nanostructures A Toolbox for N...
777K€
Cerrado
NANOTHERAPY
A Novel Nanocontainer drug carrier for targeted treatment of...
150K€
Cerrado
NANOTRAC
Tracing the Intracellular Fate of Anticancer Nanomedicines
100K€
Cerrado
CTQ2017-87708-R
PRODUCCION DE NANOESTRUCTURAS FUNCIONALIZADAS BASADAS EN BIO...
189K€
Cerrado
PID2019-109450RB-I00
POLIMEROS SUPRAMOLECULARES DIRIGIDOS AL MICROAMBIENTE TUMORA...
97K€
Cerrado
Información proyecto PANOPTES
Líder del proyecto
UNIVERSITY OF DURHAM
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
5M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
This project will develop methodology for the manufacture of novel peptide-based nanoparticles and nanocapsules to satisfy an unmet clinical need: sustained drug delivery to the posterior segment of the eye. The proposed consortium brings together internationally leading groups in self-assembling polypeptide nanoparticle and nanocapsule preparation by chemical (Durham) and genetic (Nijmegen) approaches, drug loading and in vitro release studies (Helsinki & Madrid), in vitro and in vivo assessment of nanoparticle biocompatibility and functionality (Helsinki, Madrid & Tübingen) and polymer synthesis, processing and industrial validation of manufacturing processes (DSM). Polyester micro- and nanoparticles that have been proposed for ocular drug delivery have several major drawbacks: acidic degradation products cause inflammation; drug release is difficult to control; and peptides and proteins are difficult to encapsulate. A platform of novel, peptide-based nanomaterials, formed through bio-inspired self-assembly processes, will be developed to overcome these problems. Peptide-based materials have a number of attractive features: biodegradation gives non-inflammatory products; self-assembly occurs under mild conditions; they possess a rich chemical diversity; they are defined at the sequence level. Polypeptides and peptide hybrid materials will be processed into nanoparticles, polymeric vesicles (polymersomes) and nanocapsules. These biodegradable and biocompatible materials will be used as containers for the loading, controlled release and cellular delivery of therapeutic molecules. The consortium therefore will enable the industrial manufacture of as-yet unobtainable, high value nanotechnology-based products utilising intrinisically low-energy demand nanobiotechnological phenomena. These will produce a step change improvement in the quality of products for sustained drug delivery to the posterior segment of the eye, enhancing the competitiveness of European industry.